专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2013189450A Eye drop preparation containing latanoprost 审中-公开
标题翻译：含有LATANOPROST的眼药水制剂
公开(公告)号：JP2013189450A
公开(公告)日：2013-09-26
申请号：JP2013104771
申请日：2013-05-17
申请人： Teika Seiyaku Kk , テイカ製薬株式会社
发明人： KIMURA TAKAHITO , WATANABE SHIZUAKI , KOBAYASHI MINORU , SEKI MAKOTO , SHIMATANI TAKAO , TAKAGI CHIHARU
IPC分类号： A61K31/5575 , A61K9/08 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/26 , A61K47/38 , A61K47/44 , A61P27/02
CPC分类号： A61K31/215 , A61K9/0048 , A61K31/5575 , A61K47/02 , A61K47/12 , A61K47/18 , A61K47/26
摘要： PROBLEM TO BE SOLVED: To provide an eye drop preparation in which degradation of latanoprost in water is prevented, adsorption of latanoprost onto a plastic container is prevented, and therefore decrease in a latanoprost content is suppressed satisfactorily.SOLUTION: An eye drop preparation is composed of components (A) to (C): (A) latanoprost; (B) a nonionic surfactant; and (C) an organic acid having two or more carboxy groups or a pharmaceutically acceptable salt thereof. Optionally, the eye drop composition is composed of, in place of (C), following components (D) and (E): (D) an organic amine and/or sugars or a derivative thereof; and (E) boric acids and/or phosphoric acids.
摘要翻译：要解决的问题：提供防止水中拉坦前列素降解的滴眼剂制剂，可以防止拉坦前列素吸附在塑料容器上，因此抑制了拉坦前列素含量的降低。解决方案：组合滴眼液制剂的组分（A）至（C）：（A）拉坦前列素; （B）非离子表面活性剂; 和（C）具有两个以上羧基的有机酸或其药学上可接受的盐。任选地，滴眼剂组合物代替（C）由以下组分（D）和（E）组成：（D）有机胺和/或糖或其衍生物; 和（E）硼酸和/或磷酸。

2. 发明专利

JP2006298907A Eye drop 审中-公开
标题翻译：眼药水
公开(公告)号：JP2006298907A
公开(公告)日：2006-11-02
申请号：JP2006076083
申请日：2006-03-20
申请人： Kowa Co , Teika Seiyaku Kk , テイカ製薬株式会社 , 興和株式会社
发明人： KIMURA TAKAHITO , AOKI TAKAHIKO , KOBAYASHI MINORU , INAGI TOSHIO , KANEBAKO MAKOTO
IPC分类号： A61K31/734 , A61K31/353 , A61K33/00 , A61K33/26 , A61K45/00 , A61P27/02 , A61P27/06 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To obtain an eye drop that further enhances intraocular pressure lowering effect than a single use of a nitric oxide donative compound and treats glaucoma, ocular hypertension, etc., without using a multiple drug.
SOLUTION: The eye drop comprises a nitric oxide donative compound and alginic acid or its salt. The method for enhancing the efficacy of a nitric oxide donative compound comprises adding alginic acid or its salt to the eye drop comprising a nitric oxide donative compound as an active ingredient. The efficacy enhancer of a nitric oxide donative compound comprises alginic acid or its salt as an active ingredient.
COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：要解决的问题：为了获得与单次使用一氧化氮供体化合物相比进一步提高眼内压降效果的眼药水，并且不使用多种药物治疗青光眼，高眼压症等。解决方案：滴眼剂包含一氧化氮供体化合物和藻酸或其盐。提高一氧化氮供体化合物功效的方法包括向包含一氧化氮供体化合物的滴眼剂中加入海藻酸或其盐作为活性成分。一氧化氮供体化合物的功效增强剂包含海藻酸或其盐作为活性成分。版权所有（C）2007，JPO＆INPIT

3. 发明专利

JP2012062269A Eye drop for corneal epithelial defect treatment 有权
标题翻译：眼部上皮缺损治疗眼损伤
公开(公告)号：JP2012062269A
公开(公告)日：2012-03-29
申请号：JP2010207110
申请日：2010-09-15
申请人： Teika Seiyaku Kk , テイカ製薬株式会社
发明人： SHIMATANI TAKAO , KOBAYASHI MINORU , ARAKI TAKASHI , ARIKAWA CHIKAKO
IPC分类号： A61K31/728 , A61K9/08 , A61K47/02 , A61K47/04 , A61K47/12 , A61K47/18 , A61P27/02
摘要： PROBLEM TO BE SOLVED: To provide a multi-dose type eye drop for corneal epithelial defect treatment containing hyaluronic acid at a high concentration of ≥0.3 w/v%, which has low cytotoxicity, is effectively prevented from decomposing thereby having high preservation efficacy and which has low irritation and satisfactory sense of use.SOLUTION: The multi-dose type eye drop for corneal epithelial defect treatment contains the following (a) to (c): (a) hyaluronic acid or its pharmacologically acceptable salt; (b) boric acid and/or borax; and (c) composed of the following (c1) and/or (c2): (c1) chlorhexidine or its pharmacologically acceptable salt; and (c2) p-hydroxy-benzoateester, wherein the blending quantity of the (a) hyaluronic acid or it pharmacologically acceptable salt is ≥0.3 w/v% to the whole of the formulation.
摘要翻译：要解决的问题：为了提供含有高浓度≥0.3w/ v％的透明质酸（其具有低细胞毒性）的角膜上皮缺损处理的多剂量眼滴，有效地防止了分解，从而具有高的保鲜效果好，刺激性低，使用感好。解决方案：角膜上皮缺损治疗的多剂量眼滴包含以下（a）至（c）：（a）透明质酸或其药理学上可接受的盐; （b）硼酸和/或硼砂; 和（c）由以下（c1）和/或（c2）组成：（c1）氯己定或其药理学上可接受的盐; 和（c2）对羟基苯甲酸酯，其中（a）透明质酸或其药理学上可接受的盐的配合量相对于整个制剂为≥0.3w/ v％。版权所有（C）2012，JPO＆INPIT

4. 发明专利

JP2009256281A Isopropyl unoprostone containing ophthalmic preparation formulation 审中-公开
标题翻译：包含眼科制剂制剂的异丙基异吲哚酮
公开(公告)号：JP2009256281A
公开(公告)日：2009-11-05
申请号：JP2008109926
申请日：2008-04-21
申请人： Teika Seiyaku Kk , テイカ製薬株式会社
发明人： SHIMATANI TAKAO , WATANABE SHIZUAKI , KOBAYASHI MINORU , SEKI MAKOTO
IPC分类号： A61K31/5575 , A61K9/08 , A61K47/02 , A61K47/12 , A61K47/18 , A61K47/34
摘要： PROBLEM TO BE SOLVED: To prevent underwater decomposition of isopropyl unoprostone and to thereby provide an opthalmic preparation formulation in which the content depletion of isopropyl unoprostone is fully controlled.
SOLUTION: The ophthalmic preparation formulation comprises the following components (A)-(D): (A) isopropyl unoprostone, (B) an organic amine, (C) a buffer and (D) a nonionic surfactant.
COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：要解决的问题：为了防止异丙基异佛石的水分解，从而提供完全控制异丙基异佛石的内含物消耗的眼药水制剂。（A） - （D）：（A）异丙基异佛石，（B）有机胺，（C）缓冲剂和（D）非离子表面活性剂。版权所有（C）2010，JPO＆INPIT

5. 发明专利

JP2009196988A Ophthalmic agent 有权
标题翻译： OPHTHALMIC代理
公开(公告)号：JP2009196988A
公开(公告)日：2009-09-03
申请号：JP2009013505
申请日：2009-01-23
申请人： Teika Seiyaku Kk , テイカ製薬株式会社
发明人： SHIBUYA FUMINORI , SUGIYAMA KIYOSHI , ITO KIYOMI , FUJISHITA SHIGETO , KOBAYASHI MINORU
IPC分类号： A61K31/365 , A61K31/245 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/32 , A61K47/34 , A61P27/02
摘要： PROBLEM TO BE SOLVED: To provide a stable and transparent ophthalmic agent containing fluorescein or its salt and oxybuprocaine or its salt and an ophthalmic agent which allows a long term storage at room temperature and under an unshaded environment.
SOLUTION: The ophthalmic agent is for storage in plastic containers and contains one or not less than two kinds of preservatives selected from the group consisting of (A)-(E): (A) fluorescein or its salt, (B) oxybuprocaine or its salt, (C) a compound having buffer action, (D) a povidone and/or a nonionic surfactant, (E) sorbic acid and its salt, and paraben. Further the agent satisfies any one of the conditions (d1), (d2), and (d3): (d1) the amount of the povidone mixed is not less than 15 w/v% of the total amount of the ophthalmic agent, (d2) the amount of a povidone mixed is less than 15 w/v% of the total amount of the ophthalmic agent and including a nonionic surfactant, and (d3) free of a povidone and including a nonionic surfactant.
COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：提供一种含有荧光素或其盐的稳定且透明的眼用药剂和奥布对卡因或其盐和允许在室温和无阴影环境下长期储存的眼科剂。（A） - （E）：（A）荧光素或其盐，（B）和（B）中的一种或不少于两种防腐剂，（C）具有缓冲作用的化合物，（D）聚维酮和/或非离子表面活性剂，（E）山梨酸及其盐和对羟基苯甲酸酯。此外，该试剂满足条件（d1），（d2）和（d3）中的任一条件：（d1）聚维酮的混合量不小于眼用试剂总量的15w / v％（ d2）混合的聚维酮的量小于眼用试剂总量的15w / v％，并且包括非离子表面活性剂，和（d3）不含聚维酮并包括非离子表面活性剂。版权所有（C）2009，JPO＆INPIT

6. 发明专利

JP2009073788A Isopropyl unoprostone-containing ophthalmic composition 审中-公开
标题翻译：含有异丙酚的含OPOTHOPO的组合物
公开(公告)号：JP2009073788A
公开(公告)日：2009-04-09
申请号：JP2007245938
申请日：2007-09-21
申请人： Teika Seiyaku Kk , テイカ製薬株式会社
发明人： SHIMATANI TAKAO , WATANABE SHIZUAKI , KOBAYASHI MINORU , SEKI MAKOTO , TAKARADA CHIHARU
IPC分类号： A61K31/5575 , A61K9/08 , A61K47/18 , A61P27/02 , A61P27/06
摘要： PROBLEM TO BE SOLVED: To obtain a clear isopropyl unoprostone-containing ophthalmic composition in which a preservative suitable for the composition is newly found and which provide a prescription exhibiting higher antiseptic and antimicrobial effect.
SOLUTION: The clear ophthalmic composition contains isopropyl unoprostone and chlorhexidine or its salt.
COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：为了获得其中新发现适用于该组合物的防腐剂并且提供具有较高抗菌和抗微生物作用的处方的透明异丙基异蓖麻油眼用组合物。
解决方案：透明眼用组合物含有异丙基异佛石和氯己定或其盐。版权所有（C）2009，JPO＆INPIT

7. 发明专利

JP2008266168A Ophthalmic agent 审中-公开
标题翻译： OPHTHALMIC代理
公开(公告)号：JP2008266168A
公开(公告)日：2008-11-06
申请号：JP2007108817
申请日：2007-04-18
申请人： Kowa Co , Teika Seiyaku Kk , テイカ製薬株式会社 , 興和株式会社
发明人： WATANABE SHIZUAKI , KOBAYASHI MINORU , TANIZAWA YOSHIO
IPC分类号： A61K31/353 , A61K47/04 , A61K47/20 , A61P27/02 , A61P27/06
摘要： PROBLEM TO BE SOLVED: To provide an ophthalmic agent for the treatment of glaucoma and ocular hypertension, containing nipradilol, and satisfying conflicting elements comprising the reduction of cell toxicity and sufficient effectiveness after preservation.
SOLUTION: The ophthalmic agent contains (A) nipradilol, (B) boric acid or a boric acid buffer solution and (C) taurine. The compounding amounts are preferably 0.05-1 w/v% for nipradilol, 0.01-4 w/v% for boric acid and 0.001-15 w/v% for taurine, and the pH is preferably 5-8.5.
COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：提供含有阿普拉洛尔的青光眼和高眼压症的治疗用眼用剂，并且满足包含细胞毒性的降低和保存后的充分效果的相互矛盾的元件。解决方案：眼用试剂含有（A）阿普拉洛尔，（B）硼酸或硼酸缓冲溶液和（C）牛磺酸。配合量对于普拉洛维胺优选为0.05-1w / v％，对于硼酸为0.01-4w / v％，对于牛磺酸为0.001-15w / v％，并且pH优选为5-8.5。版权所有（C）2009，JPO＆INPIT

8. 发明专利

JP2006045099A Transdermal patch 审中-公开
标题翻译：透明贴
公开(公告)号：JP2006045099A
公开(公告)日：2006-02-16
申请号：JP2004226987
申请日：2004-08-03
申请人： Teika Seiyaku Kk , テイカ製薬株式会社
发明人： TAKEUCHI HIDETATSU , TAKAOKA MASAFUMI , KOBAYASHI MINORU , SHIMA YUICHIRO
IPC分类号： A61K9/70 , A61K31/192 , A61K31/196 , A61K31/381 , A61K31/405 , A61K31/5415 , A61K31/618 , A61P29/00
摘要： PROBLEM TO BE SOLVED: To provide a transdermal patch that has excellent initial exudation rate and can be suitably used even when the patient wants to remove the pain at the diseased part as soon as possible.
SOLUTION: This transdermal patch is prepared by coating an aqueous plaster including medicinally active ingredients on the supporting medium in an amount of 100 g to 360 g/m
2 .
COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：提供具有优异的初始渗出速率的透皮贴剂，并且即使当患者想要尽快去除患病部位的疼痛时也可以适当使用。解决方案：通过在支撑介质上涂覆含有药物活性成分的水性膏药，其量为100g至360g / m 2 SPF，制备该透皮贴剂。版权所有（C）2006，JPO＆NCIPI

9. 发明专利

JP2004043516A Ophthalmic agent 审中-公开
标题翻译： OPHTHALMIC代理
公开(公告)号：JP2004043516A
公开(公告)日：2004-02-12
申请号：JP2003392022
申请日：2003-11-21
申请人： Teika Seiyaku Kk , テイカ製薬株式会社
发明人： KOBAYASHI MINORU , MIYAMOTO HIROMI , WATANABE SHIZUAKI , KIMURA TAKAHITO
IPC分类号： A61K47/12 , A61K31/353 , A61K45/00 , A61K47/18 , A61P27/02 , A61P27/06 , A61P27/14 , A61P37/08
摘要： PROBLEM TO BE SOLVED: To obtain an ophthalmic agent containing nipradilol or a salt thereof that is safe for eye and excellent in rotproofing effect even when a quaternary ammonium cationic surfactant used as an antiseptic is not added or added in a markedly decreased amount.
SOLUTION: This ophthalmic agent contains the nipradilol or the salt thereof and trometamol. The trometamol can bring about an excellent rotproofing effect even when an extremely small amount of the quaternary ammonium cationic surfactant is added, the leading to a practical ophthalmic agent.
COPYRIGHT: (C)2004,JPO

10. 发明专利

JP2010132572A Ophthalmic agent 审中-公开
标题翻译： OPHTHALMIC代理
公开(公告)号：JP2010132572A
公开(公告)日：2010-06-17
申请号：JP2008307471
申请日：2008-12-02
申请人： Kowa Co , Teika Seiyaku Kk , テイカ製薬株式会社 , 興和株式会社
发明人： SHIMATANI TAKAO , KOBAYASHI MINORU , SEKI MAKOTO , INAGI TOSHIO
IPC分类号： A61K31/353 , A61K47/04 , A61K47/10 , A61K47/36 , A61P27/02
摘要： PROBLEM TO BE SOLVED: To provide an ophthalmic agent which does not cause a problem of lowering in viscosity and pH with time while containing alginic acid or a salt thereof as a sustained release component.
SOLUTION: The ophthalmic agent contains (A) nipradilol, (B) phosphoric acid or a salt thereof, (C) alginic acid or a salt thereof, and (D) a polyhydric alcohol. The polyhydric alcohol is selected from glycerin, mannitol, sorbitol, and propylene glycol.
COPYRIGHT: (C)2010,JPO&INPIT

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式